Hong Kong Stock Movement: BOAN BIOTECH surged 20.46%

Hong Kong Stock Movement BOAN BIOTECH surged 20.46%. According to recent important news: On September 16, BOAN BIOTECH's stock price rose sharply due to reasonable cost control in the first half of the year. The launch of the new product, disitamab vedotin, led to a short-term decrease in gross margin, but the R&D expense ratio decreased, and the sales expense ratio fluctuated reasonably. The company has ample cash to support the advancement of its innovative drug pipeline. Huazhang Securities is optimistic about its biopharmaceutical platform capabilities and innovative pipeline potential, driving the stock price up. Data source: Zhitong Finance. The biopharmaceutical industry has significant innovation potential. Stocks with High Trading Volume in the Industry Yaojie Ankang-B surged 54.58%. Based on recent important news: On September 16, Yaojie Ankang-B was included in the Hong Kong Stock Connect list, leading to a substantial increase in its stock price. This move increased market liquidity, attracting a large influx of funds and driving the stock price to soar. On September 10, Yaojie Ankang announced that its core product, tepotinib combined with furmonertinib, received clinical implied approval from the China National Medical Products Administration, generating high market expectations for its future development and further stimulating the stock price increase. Recently, Yaojie Ankang's stock price and trading volume experienced abnormal fluctuations. The company's board stated that it was unaware of any reasons for the anomalies, raising market doubts about the rationality of its valuation. The Hong Kong innovative drug market is booming, with strong liquidity. Tongyuan Kang Pharmaceutical-B surged 35.18%. According to recent key news: On September 15, Tongyuan Kang Pharmaceutical-B announced that Zhang Senquan resigned from his position as an independent non-executive director. The market interpreted this as an adjustment in the company's governance structure, which may bring new development opportunities, driving the stock price up. The market reacted positively to the changes in the company's governance. Kangfang Biologics rose 1.86%. Based on recent important news: On September 16, Kangfang Biologics' self-developed anti-CD47 monoclonal antibody, lifirafenib, received orphan drug designation from the U.S. FDA for the indication of acute myeloid leukemia. This progress enhanced market confidence in the company's innovation capabilities, driving the stock price up. On September 15, Kangfang Biologics announced that its cadonilimab for PD-1 resistant hepatocellular carcinoma completed the first patient dosing in its global registration trial. This marks another significant advancement for the company in the field of tumor immunotherapy, boosting investor confidence. On September 15, Kangfang Biologics showcased excellent anti-tumor activity data for cadonilimab combined with lenvatinib for the treatment of advanced hepatocellular carcinoma at the 2023 ESMO conference, further enhancing market confidence in its product portfolio. The biopharmaceutical industry is active in innovation, with high market attention. Stocks with High Market Capitalization in the Industry BeiGene fell 1.90%. According to recent important news: On September 15, the National Healthcare Security Administration launched a new pricing mechanism for newly listed drugs, allowing innovative drugs to have greater pricing flexibility and a price protection period in the early stages of listing. This policy enhances the market competitiveness of innovative drug companies like BeiGene, accelerating the commercialization of their products On September 16, BeiGene announced a 45.78% growth in product revenue for the first half of 2025, with BaYueZe® contributing over 70% of the revenue. The strong demand for the product in the global market and favorable net pricing drove the company's performance growth. On September 12, there were rumors in the market that the United States might impose restrictions on Chinese innovative drugs, which put pressure on the innovative drug sector in the short term. However, in the long term, China's biotechnology technology continues to make breakthroughs, with frequent overseas transactions, and the development prospects remain positive. The innovative drug sector is driven by favorable policies